Vertex Pharmaceuticals Incorporated has announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis $(CF)$ in individuals aged 6 years and older with at least one non-class I mutation in the CFTR gene. This approval allows approximately 31,000 people with CF in the European Union to access this new, highly effective modulator therapy, which has shown superior results in improving CFTR protein function compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor). The approval marks a significant step towards enhancing CF care by providing a once-daily medication that delivers greater reductions in sweat chloride, ultimately improving patient outcomes. Vertex Pharmaceuticals is committed to working with reimbursement bodies across EU member states to ensure swift access for all eligible patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.